Many pharmaceutical companies still prefer to deal with their stakeholders one-by-one in a controlled way. They are often at their most comfortable dealing with clinical opinion leaders, talking about the benefits of their products. But are they missing a trick?
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.